This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Consensus Statement on Panic Disorder From the International Consensus Group on Depression and Anxiety

James C. Ballenger, M.D.; Jonathan R. T. Davidson, M.D.; Yves Lecrubier, M.D.; and David J. Nutt, M.D., Ph.D. (International Consensus Group on Depression and Anxiety); and David S. Baldwin, M.R.C.Psych.; Johan A. den Boer, M.D., Ph.D.; Siegfried Kasper, M.D.; and M. Katherine Shear, M.D.

Published: August 1, 1998

Article Abstract

Objective: To provide primary care clinicians with a better understanding of management issues in panicdisorder and guide clinical practice with recommendations for appropriate pharmacotherapy. Participants:The 4 members of the International Consensus Group on Depression and Anxiety were James C. Ballenger(chair), Jonathan R. T. Davidson, Yves Lecrubier, and David J. Nutt. Four faculty invited by the chairmanalso participated: David S. Baldwin, Johan A. den Boer, Siegfried Kasper, and M. Katherine Shear.Evidence: The consensus statement is based on the 6 review papers that are published in this supplement andon the scientific literature relevant to these issues. Consensus Process: There were group meetings held duringa 2-day period. On day 1, the group discussed each review paper and the chairman and discussant (Dr.Kasper) identified key issues for further debate. On day 2, the group discussed these key issues to arrive at aconsensus view. After the group meetings, the consensus statement was drafted by the chairman and approvedby all attendees. Conclusions: The consensus statement provides standard definitions for responseand remission and identifies appropriate strategy for the management of panic disorder in a primary caresetting. Serotonin selective reuptake inhibitors are recommended as drugs of first choice with a treatmentperiod of 12 to 24 months. Pharmacotherapy should be discontinued slowly over a period of 4 to 6 months.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Frontothalamic Circuit Abnormalities in Patients With Bipolar Depression and Suicide Attempts

To identify potential markers for suicide risk, this fMRI study looked at neural activity in bipolar depression...

Read More...